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Patients with head and neck cancer often experience a significant decrease in their
quality of life during chemoradiotherapy (CRT) due to treatment-related pain, which
is frequently classified as severe. Transcranial direct current stimulation (tDCS) is a
method of non-invasive brain stimulation that has been frequently used in experimental
and clinical pain studies. In this pilot study, we investigated the clinical impact and
central mechanisms of twenty primary motor cortex (M1) stimulation sessions with
tDCS during 7 weeks of CRT for head and neck cancer. From 48 patients screened,
seven met the inclusion criteria and were enrolled. Electroencephalography (EEG)
data were recorded before and after tDCS stimulation as well as across the trial to
monitor short and long-term impact on brain function. The compliance rate during
the long trial was extremely high (98.4%), and patients mostly reported mild side
effects in line with the literature (e.g., tingling). Compared to a large standard of
care study from our institution, our initial results indicate that M1-tDCS stimulation
has a pain relief effect during the CRT that resulted in a significant attenuation of
weight reduction and dysphagia normally observed in these patients. These results
translated to our patient cohort not needing feeding tubes or IV fluids. Power spectra
analysis of EEG data indicated significant changes in α, β, and γ bands immediately
after tDCS stimulation and, in addition, α, δ, and θ bands over the long term
in the seventh stimulation week (p < 0.05). The independent component EEG
clustering analysis showed estimated functional brain regions including precuneus and
superior frontal gyrus (SFG) in the seventh week of tDCS stimulation. These areas
colocalize with our previous positron emission tomography (PET) study where there was
activation in the endogenous µ-opioid system during M1-tDCS. This study provides
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preliminary evidence demonstrating the feasibility and safety of M1-tDCS as a potential
adjuvant neuromechanism-driven analgesic therapy for head and neck cancer patients
receiving CRT, inducing immediate and long-term changes in the cortical activity and
clinical measures, with minimal side-effects.
Keywords: tDCS, EEG, head and neck cancer, pain management, chemotherapy, adjuvant
INTRODUCTION
More than 50,000 Americans are diagnosed with head and
neck cancer every year (Siegel et al., 2012). These patients
struggle with feeding, changes in physical appearance, speech,
and psychological well-being (Epstein et al., 1999; Rose-Ped
et al., 2002; Sonis, 2004a). Despite advancements in treatment
options, a majority of patients experience emotional and physical
distress (Ichikura et al., 2016), especially during treatment
as chemoradiotherapy (CRT) itself induces mucositis and
excruciating local pain that impairs food intake, leading to
escalating opioid overuse and, consequently, drug associated
side-effects (Schaller et al., 2015). Especially, radiotherapy (RT)
induces inflammation of the mouth and mucous membranes
of the throat, oral-mucositis, leading to odynophagia or painful
swallowing. In some cases, further dose increases do not provide
analgesia (Schaller et al., 2015). These treatment-induced side-
effects often result in hospitalization and breaks in treatment,
which translate to lower locoregional control and survival rates
(Sonis, 2004a).
Recent studies have shown the efficacy of non-invasive brain
stimulation in acute and chronic pain alleviation (Hosobuchi,
1986; Nitsche and Paulus, 2000; Fregni et al., 2006; Zaghi
et al., 2011; Dasilva et al., 2012; Luedtke et al., 2012; O’Connell
et al., 2014; Vaseghi et al., 2014). Transcranial direct current
stimulation (tDCS) is a brain stimulation technique that applies
a weak direct current to the scalp that flows from anode
to cathode electrodes, which tend to increase and decrease
cortical excitability, respectively. Studies revealed that half of
tDCS current diffuses across the scalp while sufficient current
penetrates the scalp and skull to influence transmembrane
neuronal potentials and modulate neuronal excitability in the
cortex without eliciting action potentials (Wagner et al., 2007).
The immediate effects of tDCS are due tomodulation of neuronal
membrane potentials at subthreshold levels, which increases or
decreases the rate of action potential firing. Usually, anodal
stimulation will depolarize membranes to subthreshold levels
and increase cortical excitability while cathodal stimulation
will hyperpolarize membranes and decrease cortical excitability
(Nitsche and Paulus, 2001). Therefore, the efficacy of tDCS is
influenced by parameters such as electrode position and current
strength (Nitsche et al., 2005; Fregni et al., 2006). Previous
studies suggest that primary cortex stimulation using tDCS was
an effective tool for alleviating chronic pain. While the precise
mechanism of this analgesia is unclear, growing evidence suggests
that motor cortex stimulation triggers rapid phasic activation
in the lateral thalamus, which results in modulation of activity
in other pain related regions such as the medial thalamus,
ventrolateral thalamus, insula, anterior cingulate gyrus, and
upper brainstem (e.g., periaqueductal gray matter) (García-
Larrea et al., 1999; Garcia-Larrea and Peyron, 2007). More
specifically, lateral thalamic modulation leads to inhibition
of thalamic sensory neurons, cingulate modulation leads to
decreased emotional appraisal of pain, and periaqueductal gray
modulation leads to descending inhibition toward the spinal
cord (Garcia-Larrea and Peyron, 2007). Evidence suggests motor
cortex stimulation may also cause endogenous opioid release
and directly inhibit the somatosensory cortex (Garcia-Larrea
and Peyron, 2007). Besides the anode placement at motor
cortex, studies also suggested the prefrontal cortex (PFC) appears
to mediate affective networks associated with pain (Boggio
et al., 2008). Recently, our group investigated, using the µ-
opioid specific radiotracer [11C] carfentanil, the immediate
effect of conventional primary motor cortex - supraorbital
(M1-SO) tDCS application in healthy subjects with positron
emission tomography (PET) imaging (Mendonca et al., 2011).
We demonstrated that tDCS application induced µ-opioid
system activation in several pain-related regions, including
the periaqueductal gray matter (PAG), dorsolateral prefrontal
cortex (DLPFC) and pre-cuneus (DosSantos et al., 2012, 2014).
Such findings suggest that we could potentially activate the
endogenous µ-opioid system, one of the most important
analgesic-related mechanisms in the brain, in head and neck
cancer patients undergoing treatment, with the intent to decrease
their pain suffering and improve quality of life during CRT.
Electroencephalogram (EEG) is an inexpensive and non-
invasive measure of brain activity, with the advantage of
high temporal resolution (milliseconds) and direct measure of
neuronal activity in the human brain. EEG is frequently used
to address the dynamics of brain processing of pain perception.
Particular pain presents characteristically in EEG demonstration
in terms of frequency and region. Moreover, using independent
component analysis (ICA) and the independent component
clustering (ICC) method, it is possible to estimate the stimulus
evoked functional brain regions. These features greatly increase
the value of using EEG in clinical pain studies. Researchers have
been able to show the use of EEG in pain mechanism studies
for both acute and chronic pain (Chen et al., 1983; Bromm
and Lorenz, 1998; Seidel et al., 2015), including tonic cold pain
(Chang et al., 2002) and chronic neuropathic pain (Bromm and
Lorenz, 1998; Sarnthein et al., 2006). In addition, analgesic drugs
can also trigger particular EEG alterations in the brain (Hartley
et al., 2014; Graversen et al., 2015), and the pain-relieving effect
varies according to individual baseline brain activity (Jensen
et al., 2014).
In this feasibility study, our aim was to investigate and
modulate the CRT induced mucocitis pain (inflammatory)
regulatory cortical mechanisms in advanced head and neck
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cancer patients.While understanding central mechanisms related
to pain using neuroimaging is important, it is equally important
to develop novel clinical protocols aimed at relieving CRT-
induced pain in head and neck cancer patients.
MATERIALS AND METHODS
Subjects
Patients with a head and neckmalignancy were recruited through
the University of Michigan Health System (UMHS) Department
of Medical Oncology and weekly tumor board meetings. Patients
were screened by the Medical Oncology clinical studies team
and then approached by H.O.P.E. lab study team members
for discussion of the protocol and informed consent. Inclusion
criteria were (1) AJCC Stage III-IV head and neck malignancy
scheduled for definitive chemoradiotherapy or radiation therapy
only; (2) patients capable of understanding and adhering to the
protocol requirements; (3) patients between the ages of 18–75
years. Emphasis was placed on patients with no current chronic
pain conditions or use of narcotic medications; (4) all patients
entered into the current protocal had biopsy confirmed head and
neck squamous cell carcinoma (HNSCC). Exclusion criteria: (1)
substantial dementia; (2) actively being treated for another cancer
at the time of enrollment; (3) any condition that would prevent
the use of tDCS, including skull abnormality, implanted metal,
implanted electronic device, seizure disorder, or other neurologic
conditions;(4) the use of an investigational drug or device within
30 days of study screening.
Patients were evaluated for dental clearance at the University
of Michigan Hospital Dentistry Clinic as part of the pre-
established standard of care. This protocol (HUM00078942)
was approved by the University of Michigan Institutional
Review Board. Written informed consent was obtained from all
participants.
From 48 patients screened, seven met the inclusion criteria
and were enrolled. Six patients were placed into the stimulation
arm of the study, with the fifth patient withdrew during the
third week of CRT due to CRT-related side effects (Table 1). Five
patients completed the study according to the outlined protocol.
The seventh patient was placed into the control arm of the study
and completed the study according to the protocol, however, this
patient was excluded from further EEG data analysis because
of lack of sufficient data, since the signal quality in half of the
data files of the specific patient failed to pass the visual data
examination. A possible reason for this might be loose contact
between EEG electrode and scalp. A brief report of chemotherapy
agents used as well as the total radiation dose delivered can be
found in Table 1.
For comparison we used data from two previous studies at
our Institution consisting of head and neck cancer patients who
did not receive tDCS or any other investigational drug or device
(HUM 000221 and 000584), which was provided to us by the
Department of Radiation Oncology. These two studies examined
MRI techniques for patients with head and neck cancer, and
only the UMHS standard of care was provided to this group,
which provided additional data from a patient cohort similar
to our control patient cohort. Baseline and 1-month follow-up
quality of life questionnaires (UWQoL), toxicity evaluations,
and weight tracking were performed for these patients, similar
to baseline and 1-month follow-up information collected from
patients enrolled in our study. Of the 97 patients enrolled in
that study, 93 met the requirements of our study and the data
from these patients were analyzed. These patients received the
standard of care while undergoing CRT and served as controls
for our study.
Neuroimaging and Transcranial Direct
Current Stimulation (tDCS)
Once placed into their assigned study arms, patients presented 1
week prior to the start of CRT for the pre-study visit, consisting
of a 20min EEG recording, as well as questionnaires and data
collection. During the first week of CRT, only questionnaires and
data collection were completed. During weeks 2 and 3 of CRT,
patients received daily tDCS stimulations (five per week), and
completed weekly and daily questionnaires. During weeks 4 and 5
of CRT, patients received three tDCS stimulations per week; and
During weeks 6 and 7, patients received two tDCS stimulations
per week. In total, 20 tDCS sessions were applied across 6
weeks (5/5/3/3/2/2)(Figure 1). EEG was recorded for 10min
prior to, during, and for 10min after tDCS stimulation at the
first appointment of the second, third and seventh stimulation
weeks. Additionally, EEG recordings were taken at the 1-week
and 1-month follow-up appointments. If patients were unable
to complete the stimulation or missed an appointment (due to
weather, emergency, holiday, etc.), the stimulation appointment
was rescheduled for the day before or the day after. If two
stimulations were required on the same day to make up a missed
appointment, one stimulation was performed in the morning
and one in the afternoon, with a minimum of 3 h in between
stimulation appointments.
The 25 cm2 sponge-pad tDCSmontage consisted of the anodal
electrode placed on the left primary motor cortex (M1) at
the location of C5 (according the 10–20 intermediate Modified
Combinatorial Nomenclature EEG system) and the cathode
electrode placed on the right DLPFC at the location of F4
(Figure 2).
Stimulation consisted of 2mA of tDCS for 20min, with a 30 s
ramp up and cool down. During simultaneous stimulation/EEG,
the stimulation electrodes were placed at C5 (anode) and F4
(cathode), and Ag/AgCl ring electrodes for EEG were placed at
P3, Cz, Fz, F3, FP1, and FP2 (Figure 2). A prefabricated cap
(Neuro Electrics, Spain), with previously perforated holes and a
chin-strap was used to mount the electrode. The proper size cap,
small, medium, or large, was determined at the pre-study visit.
Approximately 6mL of 0.9% Saline solution was used per sponge
electrode for conductivity. Approximately 12mL of Lectron II
Conductivity Gel was then injected into the EEG electrode sites
when applicable. Neuroelectrics StarStim (Neuro Electronics,
Spain) software was used to control stimulation and EEG settings,
monitor impedance and time intervals, and record EEG data.
Pain Level Assessment
We selected the visual analog scale (VAS), percentage of
weight loss, and common terminology criteria for adverse
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TABLE 1 | Basic characteristics of stimulation patients.
ID ENROLL AGE SEX GROUP Disease Tobacco Quit? Quit Planned cumulative Carboplatin Paclitaxel Cisplatin
DATE site history year radiation dose (Gy/day) (AUC 1) (mg/m2) (mg/m2)
1 11/21/14 56 Male Stimulation Oropharynx Yes Yes 2014 70.00 Yes 30 N/A
2 12/15/14 67 Male Stimulation Oropharynx Yes Yes 1994 70.00 Yes 30 N/A
3 01/21/15 63 Female Stimulation Oral Cavity No 66.00 No N/A 40
4 02/20/15 69 Male Stimulation Oropharynx No 70.00 Yes 30 N/A
6 03/04/15 58 Male Stimulation Oropharynx Yes No 70.00 Yes 30 N/A
FIGURE 1 | Study Protocol (* denotes simultaneous stimulation and EEG recording).
events (CTCAE) as indices to reflect the level of pain patients
experienced during CRT. To further evaluate the tDCS treatment
effect, we also used the McGill and positive and negative affect
schedule (PANAS) questionnaires before and after each tDCS
session. For patients in the stimulation arm, weight wasmeasured
regularly as an objective measure of nutritional status, and has
been used in numerous other head and neck radiotherapy trials,
including oral mucositis mitigation trials (Gellrich et al., 2015).
While for patients in control arm, weight was measured at
baseline and 1 month following the regular treatment. Dysphagia
was recorded at weekly oncology visits for all patients in the
stimulation arm. The CTCAE v3.0 has been used since 2006 at
University of Michigan Health System (UMHS), and varied little
from v2.0 regarding the grading of dysphagia. During the CRT
process, the patients were taking oral morphine equivalent as
analgesic drug.
EEG Data Analysis
The EEG data analysis was completed in EEGLAB (a matlab
based software, Mathworks) (Delorme and Makeig, 2004).
For preprocessing, the raw data were firstly high-pass filtered
at >1Hz using basic FIR filter function. Then automatic
channel rejection function was applied to reject the channel
using kurtosis measure and Z-score threshold at 5. Then the
filtered data were visually inspected to remove the artifacts
and noisy parts. Next, the Run ICA function was used to
conduct an ICA process on the data. Finally the functional
EEG dipoles were estimated for each patient using DIPFIT 2.x
tool in EEGLAB based on the ICs calculated from the previous
step.
The post-processing steps consisted of two parts. The first part
was power spectrum comparisons for all channels respectively
between pre/post tDCS stimulation and between pre-study visit
week/seven of tDCS stimulation. We used the Precompute
channel measures and Plot channel measures functions to
compare the EEG power spectra before/after as well as pre-study
visit week/week 7 of tDCS. The comparison frequency bands
ranged from 0 to 50Hz. The EEG lab statistics were used and
the threshold was set to be p < 0.05. The second part was
to cluster independent components across patients and estimate
the locations of group-level functional EEG dipoles. The Build
pre-clustering array function was used following the Precompute
component measures. The centered MNI coordinates (with a
5mm radius voxel) of each identified IC cluster was examined
for their related brain region within the automatic anatomical
labeling (AAL) database (Tzourio-Mazoyer et al., 2002).
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FIGURE 2 | tDCS Stimulation and EEG recording setup. (A) M1-PFC tDCS set up with concurrent EEG. (B) Electric current pathway from M1 anode in red to
PFC cathode in blue. (C) tDCS anode/cathode and EEG channel locations set up.
FIGURE 3 | EEG signal sources changes to PFC and PreCuneus following 7 weeks of tDCS stimulation. The estimated locations of the EEG sources are
marked out for each stage. The blue, red, and yellow dots indicate, respectively, the sources with possible locations at SFG, PreCuneus, and other areas. (A)
Estimated signal sources before tDCS stimulation (average of week 2, 3, and 7). (B) Estimated signal sources immediately after tDCS stimulation (average of week 2,
3, and 7). (C) Estimated signal sources in pre-study visit week. (D) Estimated signal sources in week seven. (E) Estimated tDCS-induced mu-opioid activation
locations (DosSantos et al., 2014).
RESULTS
Locations of Estimated Functional EEG
Sources
Figure 3 shows the clustered ICs from 5 subjects by common
properties of their EEG data spectrums and scalp maps. The pre-
tDCS stage had three clusters separately that included estimated
functional brain regions (Week 2, 3, and 7 EEG data included):
left Anterior Cingulate Cortex (ACC) and left Medial Frontal
Gyrus (MFG) centered at (MNI: −15, 40, 16); left MFG and
Sub-Gyral centered at (−18, −2, 59); Insula, left Precentral
Gyrus (primary motor cortex), and left Superior Temporal Gyrus
(STG) centered at (−47, −12, 8). The post-tDCS stage had
four clusters separately and included estimated functional brain
regions (Week 2, 3, and 7 EEG data included): left Superior
Frontal Gyrus (SFG) centered at (−9, 12, 57); left SFG, MFG,
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and ACC centered at (−19, 45, 17); Extra-Nuclear and Insula
centered at (−47, −12, 8); Sub-Gyral, Extra-Nuclear and Insula
centered at (García-Larrea et al., 1999; Zaghi et al., 2011; Hartley
et al., 2014). The pre-study visit week tDCS stage had four clusters
separately and included estimated functional brain regions in:
Insula, Extra-Nuclear, and Sub-Gyral centered at (40, −11,
20); left STG, Supramarginal Gyrus (somatosensory association
cortex), and middle Temporal Gyrus (MTG) centered at (−44,
−58, 26); left MFG centered at (6, 61, 14); left MFG centered
at (−3, −11, 64). The week 7 tDCS stage had three clusters
separately AND included estimated functional brain regions:
Sub-Gyral, right Precentral Gyrus, Middle Frontal Gyrus, and
SFG centered at (20,−20, 66); left SFG centered at (−17, 50, 50);
and left Precuneus and Superior Parietal Lobule centered at (−20,
−63, 49). All coordinates reported were MNI coordinates.
EEG Channel Spectrum Analysis
Figure 4 indicates EEG data spectrum change right before and
after tDCS stimulus (Week 2, 3, and 7 EEG data included, power
between 0 and 50Hz frequency band were compared). Power
spectra at γ band significantly decreased immediately after tDCS
application at location F3, Fz, Cz, and P3 (p < 0.05). Power
spectra at β band significantly decreased immediately after tDCS
application at location Fz and P3 (p < 0.05). In α band, the power
spectra significantly decreased after tDCS stimulus at location Cz
and P3 (p < 0.05). Figure 5 compares EEG data spectrum in pre-
study visit week and week 7 in a long term. Power spectra at δ
band significantly increased after 7 weeks tDCS stimulation at
location Fp1, F3, Fz, Cz, and P3 (p < 0.05). Power spectra at θ
band significantly increased in week 7 at locations Fp1, Fz and Cz
compared with pre-study visit week (p < 0.05). In α band, the
power spectra significantly increased in week 7 at locations Fp1,
Fz and Cz (p < 0.05). In γ band, the power spectra significantly
increased in week 7 at location P3 (p < 0.05).
Pain Level Assessment Results
The pain level assessments were completed in primarily
three primary measures: VAS scores, weight loss and graded
dysphagia between the tDCS stimulus cohort and control cohort.
Tables 2–4, respectively, showVAS scores, weight loss and graded
dysphagia.
The five patients who completed the tDCS protocol reported
VAS at the beginning of each week. In average, 2.94 and 1.59
out of 10 were reported, respectively at baseline and 1-week
follow-up.
The five patients lost 10.12, 9.60, 9.33, 5.11, and 4.51% body
weight from baseline to 1-week follow-up (Table 2). One out of
five (20%) patients examined in this study lost >10% of their
body weight from baseline through the end of treatment. For
patients in the stimulation arm, the average body weight loss was
FIGURE 4 | EEG power spectra analysis results comparison for all channels before and immediately after tDCS stimulation (1 - 50Hz; Fp1, Fp2, Fz, F3,
Cz, and P3; average of week 2, 3, and 7). The background colors indicate EEG frequency bands: red, δ wave; orange, θ wave; yellow, α wave; green, β wave; blue,
γ wave. The green and blue lines, respectively, indicate power spectra before and after tDCS stimulation. Generally the power decreased immediately after tDCS
stimulation for α, β, and γ waves.
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FIGURE 5 | EEG power spectra analysis results comparison for all channels in the pre-study visit week and seventh week (1–50Hz; Fp1, Fp2, Fz, F3,
Cz, and P3). The background colors indicate the EEG frequency bands: red, δ wave; orange, θ wave; yellow, α wave; green, β wave; blue, γ wave. The green lines
and blue lines, respectively, indicate power spectra in the seventh week and pre-visit week of tDCS stimulation. Generally the power of δ, θ, α, and β waves increased,
while the power of γ wave decreased in channels Fp1/Fp2/P3 and increased in channels F3/Fz/Cz, after 7 weeks of tDCS stimulation.
TABLE 2 | Patient-reported pain was measured using VAS at baseline (pre-visit week), week 1–week 7 of CRT process, both one-week, and 1-month
follow-up.
ID PRE Wk1 Wk2 Wk3 Wk4 Wk5 Wk6 Wk7 WkFu MoFu
1 5.30 0.00 0.80 2.55 4.62 2.05 3.80 3.65 1.25 5.00
2 2.40 0.00 0.00 0.45 1.00 0.60 1.10 2.60 2.40 0.65
3 7.00 6.00 5.70 5.00 9.80 9.00 6.00 6.00 N/A 4.00
4 0.00 0.00 0.25 0.80 0.90 1.80 0.65 0.30 0.60 2.35
6 0.00 0.00 0.00 0.60 1.15 1.30 2.00 1.95 2.10 1.05
Ave 2.94 1.20 1.35 1.88 3.49 2.95 2.71 2.90 1.59 2.61
7.52%.Of the 93 control patients examined, 72 (77.4%) lost>10%
of their body weight, with a mean weight loss of 12.9%.
Four out of five stimulation patients reported scores of 0 at
baseline, thus only control subjects with reported scores of 0
at baseline were used for optimal comparable analysis of the
CTCAE grading system, and 64 of the control patients met
these criteria. While none of the four stimulation patients had
grade 3 dysphagia (0%), nine out of the 64 control patients that
met the criteria reached grade 3 dysphagia (14.1%). Of those
nine patients, some developed grade 3 dysphagia at week 2,
while a majority developed grade 3 dysphagia between weeks
4 and 5, barely past their halfway mark of treatment. The
difference between grade 2 (symptomatic eating/swallowing that
alters eating habits) and grade 3 dysphagia (severely altered
eating/swallowing habits), which lead to inadequate intake and
possible indication for feeding tube placement, is clinically
significant. Figure 6 shows intraoral pain area and intensity
during chemoradiation/tDCS trial for all four patients receiving
tDCS stimulation.
Assessment of oral mucositis grades, as assigned by the WHO
Oral Mucositis Grading Criteria, revealed similar scores for both
control and stimulation patients. Of the 93 control patients
examined, 90 patients had mucositis grades recorded during
CRT, with an average grade of 2.4 based on the worst grade
given during therapy. The patients in our study had an average
WHO mucositis grade of 2.5 based on the worst grade given.
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TABLE 3 | Patient weights along time course (Pre-visit, Week 1–Week 7, Following Week, Following month).
ID PRE Wk1 Wk2 Wk3 Wk4 Wk5 Wk6 Wk7 Wk Fu Mo Fu
STIMULATION GROUP
1.00 252.90 247.00 247.00 239.70 238.00 240.90 239.80 243.30 227.30 216.10
2.00 200.10 193.00 190.00 191.40 188.00 186.00 183.70 179.70 180.90 176.60
3.00 165.00 168.90 168.90 159.30 158.00 157.80 154.00 149.60 149.60 147.00
4.00 213.40 212.30 214.70 213.90 213.40 212.90 210.90 207.60 202.50 197.70
6.00 286.00 283.90 286.00 281.00 277.50 274.60 270.80 271.00 273.10 266.10
AVE
(N = 5)
223.48 221.02 221.32 217.06 214.98 214.44 211.84 210.24 206.68 200.70
PWC% N/A −1.10 −0.97 −2.87 −3.80 −4.05 −5.21 −5.92 −7.52 −10.19
CONTROL GROUP
AVE
(N = 91/72)
199.95 N/A N/A N/A N/A N/A N/A N/A 175.58 N/A
PWC% N/A -12.9
The weight variation table shows the patients’ weight at each time. The weight variation in percentage table shows the variation of weight at each time based on the pre-visit week
weight in percentage.
TABLE 4 | Weekly dysphagia grading of stimulation patients and control patients during CRT.
Group Dysphagia Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7
Control 0 60 34 9 4 3 0 0
1 1 18 28 17 17 9 5
2 0 7 21 32 33 43 39
3 0 2 2 3 7 9 7
4 0 0 0 0 0 0 0
total 61 61 60 56 60 61 51
missing 3 3 4 8 5 3 14
tDCS Stimulation 0 4 4 0 0 0 0 0
1 0 0 3 0 0 0 0
1/2 0 0 1 2 1 2 0
2 0 0 0 2 2 2 3
3 0 0 0 0 0 0 0
4 0 0 0 0 0 0 0
total 4 4 4 4 3 4 3
missing 0 0 0 0 1 0 1
The Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 has been used regarding to the grading of dysphagia. The selection criteria for this comparison is that the
patient reported 0 score at baseline. Four stimulation patients in the intervention arm are summarized and compared to the sixty-four patients in the control arm.
This suggests that tDCS has no impact on the development of
mucositis in head and neck cancer patients as expected.
To further evaluate the immediate treatment effect of tDCS
treatment on pain, Tables 5, 6 show the VAS, present pain
intensity (PPI) and PANAS scores before and after the tDCS
sessions from week 2 to week 7, respectively. Generally, the
VAS reported by patients reduced in every week after the
tDCS sessions (average decrease range: 0.19–0.57). While the
PPI indices generally decreased one grade. Both positive and
negative scores in PANAS questionnaire decreased in average
after receiving tDCS stimulation (positive decrease range:−0.25–
6.5, negative decrease range: 0.5–3.5).
DISCUSSION
The aim of our study was to test the feasibility and safety
of M1-tDCS as an adjuvant neuromechanism-driven analgesic
therapy for head and neck cancer patients receiving CRT. We
observed immediate superior frontal gyrus (SFG) activation in
response to acute tDCS stimulation and activation of the SFG
and precuneus, documented up to the seventh and final week
of tDCS stimulation. In addition, power spectra analysis of EEG
data showed significant changes in different frequency bands
indicating possible evidence of central modulatory effect on
pain. Of immediate clinical significance, the tDCS patient group
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FIGURE 6 | Intraoral Pain Area and Intensity During Chemoradiation/tDCS trial. All four patients reported only mild-to-moderate pain throughout their 7-week
course of CRT. Using the GeoPain technology (MoxyTech LLC, MI), patients are able to quickly and efficiently illustrate their pain locations and pain intensity, allowing
healthcare providers to both acknowledge current pain, as well as easily access and evaluate the patients pain history.
showed less weight loss and dysphagia during the CRT process
compared with the non-tDCS patient group, indicating less
functional effects from pain for the patients in the tDCS group.
Our first finding demonstrates that long-term EEG changes
induced by 7 weeks of tDCS colocalize with acute changes during
tDCS stimulation observed in the endogenous µ-opioid system.
In a previous study using PET, our lab used a radiotracer with
specific affinity for µ-opioid receptors, [11C]carfentanil, to test
the immediate pain threshold variation after applying M1-tDCS
(DosSantos et al., 2012). We found that a significant increase in
tDCS-induced mu-opioid receptor mediated neurotransmission
in the precuneus, PAG, and left PFC. In the current study, we
found the left precuneus and left PFC were activated in week 7,
however, we did not observe any functional activation in PAG or
other deeper regions. A possible explanation for this is that EEG
as a non-invasive imaging technique produces a weaker signal
from regions in the midbrain (Klein and Thorne, 2006).
We also documented a change in EEG power spectra in
different frequency bands immediately and after long-term use of
tDCS stimulation. Although few studies investigated clinical pain
with EEG, there were several reports of EEG in different kinds
of experimental pain (Chen and Rappelsberger, 1994; Ghione
et al., 2005; Nir et al., 2010; Peng et al., 2015; Wang et al., 2015),
however, the reported results were not consistent. α activities
seem to be most commonly reported among these studies.
Generally the lower amplitude of α activity indicates greater
cortical excitability (Peng et al., 2015). Moreover, Wang et al.
(2015) reported θ/β activity decreased in a cognitive behavior
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TABLE 5 | VAS and PPI reported by patients before and after tDCS treatment in week 2–week 7.
ID 1 2 3 4 6 Average
W2 BtDCS VAS 1.68 0.00 5.88 0.10 0.06 1.54
PPI MI/DIC NO DIT/HOR NO NO N/A
W2 AtDCS VAS 0.90 0.00 5.80 0.04 0.02 1.35
PPI NO/MI NO DIC/DIT NO NO N/A
W3 BtDCS VAS 1.80 0.50 6.40 1.20 1.04 2.19
PPI MI/DIC MI DIT/HOR NO/MI MI/DIC N/A
W3 AtDCS VAS 2.14 0.44 6.22 0.58 0.76 2.03
PPI MI/DIC MI DIT/HOR NO/MI MI/DIC N/A
W4 BtDCS VAS 2.90 0.90 8.20 0.47 1.17 2.73
PPI MI/DIC MI DIT/EX NO/MI DIC N/A
W4 AtDCS VAS 1.80 0.87 8.63 0.20 1.10 2.52
PPI MI/DIC MI DIT/EX NO DIC N/A
W5 BtDCS VAS 2.27 0.67 8.90 1.07 1.00 2.78
PPI MI/DIC MI HOR/EX MI DIC N/A
W5 AtDCS VAS 0.00 0.67 9.10 0.47 0.83 2.21
PPI NO/MI MI HOR/EX MI DIC N/A
W6 BtDCS VAS 2.00 1.60 7.20 0.45 1.85 2.62
PPI DIC DIC DIT/HOR NO/MI DIC N/A
W6 AtDCS VAS 1.00 1.55 7.40 0.60 1.60 2.43
PPI NO/MI DIC DIT/HOR NO/MI DIC N/A
W7 BtDCS VAS 3.80 2.65 8.60 0.30 1.50 3.37
PPI MI/DIC DIC DIT/EX NO DIC N/A
W7 AtDCS VAS 2.20 2.45 9.05 0.35 1.15 3.04
PPI NO/MI DIC DIT/EX NO DIC N/A
therapy group. In our study, immediately after tDCS stimulation,
the α activity at Cz and P3 positions decreased significantly,
indicating cortical excitability increases in the proximity of the
tDCS electrodes.We also observed β activity decrease at positions
Fz and P3 and γ activity decrease at positions F3, Fz, Cz, and
P3. Arguably γ waves are implicated in creating the unity of
conscious perception and meditation (Singer and Gray, 1995)
and its sequence of heightened sense of consciousness, bliss,
and intellectual acuity. Notably, meditation is known to have a
number of health benefits including pain relief (Zeidan et al.,
2015). In the long term, after 7 weeks of tDCS stimulation, our
EEG results revealed a different pattern. α activity increased at
locations Fp1, Fz and Cz, showing that cortical excitability under
the path from anodal to cathodal decreased after long-term tDCS
stimulation. δ/θ activities generally increased, and in channel P3
close to tDCS anodal γ activity decreased. Increased slow-wave
activity, especially θ activity, and reducing fast-wave activity was
detected in mental therapies for pain including neurofeedback
treatment, hypnosis andmeditation (Sime, 2002; Fell et al., 2010).
Considering that all these therapies involved cognitive changes
in the brain, it would be reasonable, based on these findings,
to suggest that the increases in slower wave activity (e.g., θ and
α) and decreases of faster wave activity (e.g., β) in our tDCS
study, provides physical neuromodulation to reduce clinical pain.
Further studies are warranted to investigate specific mechanisms
of tDCS stimulation in pain relief.
Stimulation using tDCS in the current clinical study reduced
patients’ pain during CRT and improved quality of life. We
monitored patients’ weight loss and reported dysphagia as indices
of pain level during their CRT. Studies have shown that during
CRT for head and neck cancer, the pain level correlated with
patients’ weight loss and dysphagia (Gellrich et al., 2015). The
average weight loss of our tDCS cohort was 7.52% compared
to 12.9% of the standard of care cohort. The CTCAE graded
dysphagia at grade >2 were 0% for the tDCS stimulation cohort
and 14.1% for the control cohort. The severity of mucositis in
our patients ranged from grade 0 to grade 4, and the amount
of patient-reported pain varied greatly from patient to patient.
Of the four stimulation patients examined, mucositis grades of
2 and 3 were seen, but none were scored higher than a grade
2 on the CTCAE dysphagia scale. Meanwhile, 14.1% of the
64 control patients reached scores of grade 3 on the CTCAE
scale. Additionally, all four reported only mild-to-moderate pain
throughout their 7-week course of CRT.
Oral Mucositis is characterized by ulceration of the mucosa,
leading to pain and dysphagia, and has been reported to occur
in 75–90% of patients undergoing chemo and radiation therapy
for head and neck cancer (Trotti et al., 2003; Sonis, 2004a,b;
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TABLE 6 | PANAS results reported by patients before and after tDCS treatment in week 2–week 7.
ID 1.00 2.00 3.00 4.00 6.00 Average
WEEK 2 Stim1BtDCS Positive N/A N/A N/A 30.00 42.00 36.00
Negative N/A N/A N/A 10.00 11.00 10.50
Stim1AtDCS Positive N/A N/A N/A 18.00 41.00 29.50
Negative N/A N/A N/A 10.00 10.00 10.00
WEEK 3 Stim1BtDCS Positive N/A N/A 20.00 13.00 41.00 24.67
Negative N/A N/A 18.00 10.00 14.00 14.00
Stim1AtDCS Positive N/A N/A 13.00 13.00 40.00 22.00
Negative N/A N/A 12.00 10.00 10.00 10.67
WEEK 4 Stim1BtDCS Positive N/A N/A 12.00 11.00 39.00 20.67
Negative N/A N/A 15.00 10.00 11.00 12.00
Stim1AtDCS Positive N/A N/A 11.00 10.00 40.00 20.33
Negative N/A N/A 13.00 10.00 11.00 11.33
WEEK 5 Stim1BtDCS Positive N/A N/A 10.00 10.00 39.00 19.67
Negative N/A N/A 14.00 11.00 11.00 12.00
Stim1AtDCS Positive N/A N/A 10.00 10.00 39.00 19.67
Negative N/A N/A 11.00 10.00 11.00 10.67
WEEK 6 Stim1BtDCS Positive N/A 34.00 10.00 10.00 38.00 23.00
Negative N/A 14.00 12.00 10.00 11.00 11.75
Stim1AtDCS Positive N/A 34.00 10.00 10.00 39.00 23.25
Negative N/A 12.00 13.00 10.00 11.00 11.50
WEEK 7 Stim1BtDCS Positive N/A 31.00 21.00 14.00 39.00 26.25
Negative N/A 12.00 32.00 10.00 11.00 16.25
Stim1AtDCS Positive N/A 28.00 13.00 13.00 40.00 23.50
Negative N/A 12.00 18.00 10.00 11.00 12.75
Scully et al., 2006). Mucositis most commonly affects themovable
mucosa, including the tongue and buccal mucosa. The pain
associated with mucositis results in a significant decrease in the
patients’ ability to eat, swallow, and talk (Sonis, 2004a). The
severity of the pain can lead to treatment breaks or dose reduction
of chemotherapy (Scully et al., 2006; Elting et al., 2008). By the
second week of therapy, ulcerations develop throughout the oral
cavity and oropharynx, requiring opioid treatment (Trotti et al.,
2003; Sonis, 2004b; Murdoch-Kinch and Zwetchkenbaum, 2011).
Multiple studies and drugs are in development to relieve patients
of OM, but little success has been found (Sonis, 2004b; Scully
et al., 2006). Because of this, opioids are the primary method of
current analgesic relief. Patients that do develop oral mucositis
are four times more likely to be hospitalized due to pain and
malnutrition compared to patients that do not develop OM. The
symptoms can last 1–2 weeks after the end of treatment, but may
last longer depending on the severity implying that head and
neck cancer patients may suffer from pain and discomfort for
5–10 weeks. Although we did not see changes in oral mucositis
prevalence or severity as a result of tDCS application, we noticed
that tDCS application reduce pain in patients with CRT-induced
oral mucositis.
Four out of the five stimulation patients analyzed had
decreases in body weight <10%, with a mean loss of 7.52%
with standard deviation 2.7%, an excellent sign of long-term
prognosis. The average weight loss of patients with head and
neck cancer undergoing CRT was found to be 12.9% with
standard deviation 5.6% in the control cohort for this study at
our institution. Loss of total body weight >10% often produces
higher co-morbidities and a worse prognosis in CRT patients
(van Bokhorst-de van der et al., 1999; Argiris et al., 2004; Liu
et al., 2006; Capuano et al., 2008). Platek et al. retrospectively
reviewed 140 patients receiving chemoradio- or radiotherapy and
found amedian weight loss of 8.56%, classified as clinically severe
(Platek et al., 2013). Ottosson et al. retrospectively examined
203 patients and found that at 5-months post-RT 77.8% of
their patients suffered from weight loss >10% (Ottosson et al.,
2014). Both studies emphasized multiple contributing factors
to the weight loss, including dysphagia, xerostomia, radiation-
induced mucositis, and other related toxicities. The mean
weight loss percentages from these studies are higher than our
stimulation patient average, but lower than our control average.
As patients undergoing tDCS treatment may have altered pain
perception, these patients may be able to better tolerate food
intake, and thus report reduced weight loss at the end of
therapy.
To further evaluate the tDCS treatment effect, we also used
the McGill (VAS and PPI scores) and positive and negative
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affect schedule (PANAS) questionnaires before and after the each
tDCS session. Patients generally reported reducedVAS scores and
lower grade PPI indices after receiving the tDCS stimulation,
indicating the tDCS has immediate effect of pain relief effect.
However, the reduction scale is relatively small and due to limited
number of patients, it is hard to statistically compare the scores
before and after the stimulations. Both the positive and negative
scores reported by patients reduced after tDCS stimulation
in every week. These results indicate that cathode PFC tDCS
applied in the current study was associated with analgesia for
both unpleasantness and intensity ratings. Which aligned with
a previous repetitive transcranial magnetic stimulation (rTMS)
study that applied stimulation on DLPFC (Borckardt et al., 2011).
These findings may potentially justify the DLPFC placement of
tDCS stimulation.
This study has several limitations: First, the patient number
recruited in the current protocol was small, leading to
difficulties in statistics across patients; and second, MRI
scanning information did not accompany EEG data for
clustering analysis. We used a unique MNI 152 brain template
for the EEG channel alignment. This may generate certain
bias in group EEG functional sources location estimation.
Since this was a preliminary feasibility test study, these
entire limitations can and will be addressed in subsequent
studies.
CONCLUSION
This study gives preliminary evidence that demonstrates
the feasibility and safety of M1-tDCS as an adjuvant
neuromechanism-driven analgesic therapy for head and
neck cancer patients receiving CRT, inducing immediate and
long-term changes in the cortical activity and clinical measures,
with minimal side-effects.
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